Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer
Summarize this article with:
BiologicsInvesting Group LeaderFollow5ShareSavePlay(14min)Comment(1)SummaryCardiff Oncology posted Phase II data for onvansertib in RAS-mutated mCRC, showing a 72% ORR versus 40–45% for standard-of-care.Onvansertib’s efficacy, durability, and safety profile suggest it could become a first-line standard-of-care backbone in a $1.2B–$2.5B U.S. market.Despite positive data, CRDF trades near $1.50/share due to small sample size, data immaturity, and anticipated dilution; risk remains high.I maintain a 3/5 conviction, accumulating CRDF on technical weakness, with focus on clinical execution, capital management, and upcoming registrational trial.This idea was discussed in more depth with members of my private investing community, Compounding Healthcare. Learn More »78image/iStock via Getty Images It is a common occurrence to see the market fail to react to positive data or updates from small-cap healthcare companies. Admittedly, most of these companies are still very far from approval and are often undercapitalized to getThis article was written byBiologics9.74K FollowersFollowBiologics is a full-time healthcare investor who developed a passion for biotech and life saving therapies after working in the medical field for years. His trade focus is around innovative companies developing breakthrough therapies and/or pharmaceuticals with catalysts for potential acquisitions. He is the leader of the investing group Compounding Healthcare. Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRDF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.